About us
About us
Our team
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Research study requests
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
About us
About us
Our team
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Research study requests
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
Advocacy
Amryt Pharma supports the aims and objectives of advocacy groups working across rare and debilitating diseases to help patients and their families and carers.
Amryt is proud to be working with the following advocacy organisations
Rare Diseases
EB
HoFH
Lipodystrophy
Acromegaly
Amryt lights up for Rare Disease Day 2021
VIEW PRESS RELEASE
AMYT/ALL/005